ADC Therapeutics Showcases Innovation at J.P. Morgan Conference Amidst Advancements in ADC Technology
- ADC Therapeutics will present at the J.P. Morgan Healthcare Conference on January 15, 2026, highlighting innovation and strategy.
- The company's ZYNLONTA has received FDA and European approval, focusing on treating relapsed diffuse large B-cell lymphoma.
- ADC Therapeutics is developing a next-generation PSMA-targeting ADC to enhance treatment options and address unmet medical needs.
ADC Therapeutics Showcases Commitment to Innovation at Upcoming Healthcare Conference
ADC Therapeutics SA, a leader in the field of antibody drug conjugates (ADCs), prepares to present at the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 15, 2026. CEO Ameet Mallik will highlight the company’s advancements and strategic vision during his presentation at 10:30 a.m. PT. The event, taking place in San Francisco, serves as a significant platform for the company to engage with investors and industry stakeholders. The presentation will be available via live webcast, ensuring that a broad audience can access insights into the company’s ongoing projects and innovative approaches.
A cornerstone of ADC Therapeutics’ current portfolio is ZYNLONTA (loncastuximab tesirine-lpyl), which has gained accelerated approval from the FDA and conditional approval from the European Commission. This drug addresses a critical need in the treatment landscape for relapsed or refractory diffuse large B-cell lymphoma, specifically after two or more lines of systemic therapy. In addition to its standalone use, ZYNLONTA is under evaluation in combination therapies and earlier treatment lines, underscoring the company’s focus on optimizing patient outcomes through cutting-edge treatments. This ongoing commitment to exploring various therapeutic avenues further solidifies ADC Therapeutics’ leadership in the ADC sector.
In line with its dedication to innovation, ADC Therapeutics is advancing a next-generation PSMA-targeting ADC that incorporates a novel exatecan-based payload and a unique hydrophilic linker. This development reflects the company’s proactive stance on enhancing ADC technology and addressing unmet medical needs. With its headquarters in Lausanne, Switzerland, and operations extending to London and New Jersey, ADC Therapeutics is well-positioned to leverage its specialized capabilities in clinical development, manufacturing, and commercialization of ADCs. The press release accompanying the conference announcement includes forward-looking statements that acknowledge potential risks and uncertainties relating to clinical trials and regulatory pathways.
In other relevant news, ADC Therapeutics continues to position itself at the forefront of ADC technology, focusing on transforming patient treatment through rigorous research and innovative product development. By prioritizing strategic advancements and maintaining transparency with stakeholders, the company fosters a robust environment for growth and collaboration. For additional information about the company’s initiatives and products, interested parties can visit adctherapeutics.com or follow ADC Therapeutics on LinkedIn.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

